Stockscreener 앱 받기
20.73
0.34%
-0.07
시간 외 거래:
20.73
전일 마감가:
$20.80
열려 있는:
$21.16
하루 거래량:
213.53K
Relative Volume:
0.85
시가총액:
$524.45M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.42%
1개월 성능:
-5.69%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$20.21
$21.43
1주일 범위
$19.38
$21.52
52주 변동 폭
$13.36
$23.15
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
명칭
Lb Pharmaceuticals Inc
전화
917-450-6581
주소
575 MADISON AVENUE, NEW YORK
LBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
20.73 | 526.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 개시 | Leerink Partners | Outperform |
| 2025-10-06 | 개시 | Piper Sandler | Overweight |
| 2025-10-06 | 개시 | Stifel | Buy |
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com Canada
PR News | On the Move: The Trevor Projects Names Wong CCOThu., Jan. 8, 2026 - O'Dwyer's PR
Poplar’s $50 million Series A to ‘transform treatment of atopic diseases’ - The Pharma Letter
LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz
LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Canada
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7.7%Should You Sell? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 3.8%Here's Why - MarketBeat
Top financings 2025 - BioWorld MedTech
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - 1470 & 100.3 WMBD
Pai Panandiker Kaya Kamlesh Net Worth (2025) - GuruFocus
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000 Index - marketscreener.com
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000E Index - MarketScreener
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6%What's Next? - MarketBeat
LB Pharmaceuticals Earnings Notes - Trefis
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals added to Russell 2000 and 3000 Indexes - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals (Nasdaq: LBRX) issues inducement equity grant to incoming CCO - Stock Titan
LB Pharmaceuticals (LBRX) Stock Analysis Report | Financials & Insights - Benzinga
Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com
LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat
LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com Canada
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com India
Lb Pharmaceuticals Inc (LBRX) 재무 분석
Lb Pharmaceuticals Inc (LBRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Lb Pharmaceuticals Inc 주식 (LBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
0.90%
자본화:
|
볼륨(24시간):